Texas Permanent School Fund Corp Has $2.79 Million Stake in Roivant Sciences Ltd. $ROIV

Texas Permanent School Fund Corp reduced its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 10.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 247,742 shares of the company’s stock after selling 29,230 shares during the period. Texas Permanent School Fund Corp’s holdings in Roivant Sciences were worth $2,792,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Amundi increased its stake in shares of Roivant Sciences by 18.1% in the first quarter. Amundi now owns 398,729 shares of the company’s stock valued at $3,991,000 after buying an additional 61,214 shares during the period. Inspire Investing LLC acquired a new stake in Roivant Sciences during the 1st quarter valued at approximately $303,000. IFG Advisory LLC acquired a new stake in Roivant Sciences during the 2nd quarter valued at approximately $255,000. Valeo Financial Advisors LLC bought a new position in Roivant Sciences during the 2nd quarter worth approximately $1,145,000. Finally, Franklin Resources Inc. acquired a new position in shares of Roivant Sciences in the 2nd quarter worth approximately $997,000. Institutional investors own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In other news, major shareholder Vivek Ramaswamy sold 1,975,858 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $21.96, for a total transaction of $43,389,841.68. Following the transaction, the insider directly owned 36,350,621 shares of the company’s stock, valued at $798,259,637.16. This represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel Allen Gold sold 1,300,000 shares of the stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $20.23, for a total value of $26,299,000.00. Following the completion of the transaction, the director owned 18,047,727 shares in the company, valued at approximately $365,105,517.21. This represents a 6.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,789,184 shares of company stock valued at $260,400,767 in the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ROIV shares. Guggenheim reiterated a “buy” rating and set a $28.00 price objective on shares of Roivant Sciences in a research report on Thursday. HC Wainwright increased their price target on Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. JPMorgan Chase & Co. upped their target price on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 18th. Finally, The Goldman Sachs Group raised their target price on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $25.19.

Roivant Sciences Price Performance

ROIV stock opened at $22.41 on Friday. The stock has a market capitalization of $15.59 billion, a PE ratio of -40.02 and a beta of 1.22. The company’s 50-day moving average is $20.00 and its 200-day moving average is $15.10. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $23.47.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.